Inhaled GM-CSF in neonatal mice provides durable protection against bacterial pneumonia

Elizabeth M. Todd, Rashmi Ramani, Taylor P. Szasz, S. Celeste Morley

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Pneumonia poses profound health threats to preterm infants. Alveolar macrophages (AMs) eliminate inhaled pathogens while maintaining surfactant homeostasis. As AM development only occurs perinatally, therapies that accelerate AM maturation in preterms may improve outcomes. We tested therapeutic rescue of AM development in mice lacking the actin-bundling protein L-plastin (LPL), which exhibit impaired AM development and increased susceptibility to pneumococcal lung infection. Airway administration of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) to LPL−/− neonates augmented AM production. Airway administration distinguishes the delivery route from prior human infant trials. Adult LPL−/− animals that received neonatal GM-CSF were protected from experimental pneumococcal challenge. No detrimental effects on surfactant metabolism or alveolarization were observed. Airway recombinant GM-CSF administration thus shows therapeutic promise to accelerate neonatal pulmonary immunity, protecting against bacterial pneumonia.

Original languageEnglish
Article numbereaax3387
JournalScience Advances
Volume5
Issue number8
DOIs
StatePublished - Aug 14 2019

Fingerprint

Dive into the research topics of 'Inhaled GM-CSF in neonatal mice provides durable protection against bacterial pneumonia'. Together they form a unique fingerprint.

Cite this